10/28/2026
🚨 MAJOR NEWS FOR THE FUTURE OF PEPTIDE MEDICINE! 🧬
An exciting development for the integrative and regenerative medicine community!
The U.S. Department of Health and Human Services (HHS) has announced an important regulatory development concerning the compounding of certain peptides.
Earlier this year, six peptides received favorable recommendations from the FDA’s Pharmacy Compounding Advisory Committee:
🧬 BPC-157
🧬 TB-500
🧬 MOTS-C
🧬 Epitalon
🧬 Semax
🧬 KPV
Why is this so important?
At Aluma Wellness®, we’ve always believed that healthcare should extend beyond a one-size-fits-all approach.
Many of the innovative therapies explored in integrative, regenerative, and personalized medicine are not FDA-approved for their proposed uses. That does not mean they should be excluded from scientific investigation or thoughtful medical discussion.
We believe patients deserve access to accurate information, transparent conversations about potential benefits and risks, and individualized care informed by emerging research.
Innovation in medicine begins with curiosity, continues through research, and advances through responsible clinical practice.
We’re encouraged to see continued federal attention to peptide medicine and look forward to what the future holds.
💙 Aluma Wellness® | Advancing Personalized Wellness Since 2014
Regulatory clarification: The advisory recommendations and interim policy announcement do not constitute FDA approval. Compounded drugs are not FDA-approved, and their safety, effectiveness, and quality are not reviewed by the FDA before marketing.
LongevityMedicine MedicalInnovation
